RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10, 2019, at 1:45 p.m. ET in New York, NY.
A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the company’s corporate website, and will be archived for a minimum of 90 days.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Being evaluated in a phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, palm-sized, disposable dry powder inhaler. LIQ865, for which Liquidia has completed two phase 1 clinical trials, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. For more information visit Liquidia’s website at www.liquidia.com.
Contact Information
Investors:
Jason Adair
Vice President, Business Development and Strategy
919.328.4400
jason.adair@liquidia.com
Media:
Christy Curran
Sam Brown Inc.
615.414.8668
media@liquidia.com
Source: Liquidia Technologies, Inc.
